Relapsing-remitting experimental autoimmune encephalomyelitis (EAE), a multiple sclerosis model, is induced in mice by injection of myelin proteolipid protein (PLP) encephalitogenic peptide, PLP 139-151 , in adjuvant. In this study, prior to EAE induction, mice were vaccinated with a bacterial plasmid encoding a PLPubiquitin fusion (pCMVUPLP). During the relapse phase of EAE, clinical signs, histopathologic changes, in vitro lymphoproliferation to PLP 139-151 and interferon-γ levels were reduced in pCMVUPLP-vaccinated mice, compared to mock-vaccinated mice (controls). Lymphocytes from pCMVUPLP-vaccinated mice produced interleukin-4, a cytokine lacking in controls. Thus, pCMVUPLP vaccination can modulate the relapse after EAE induction.
Introduction
Relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) is a CD4 + T helper (Th) type 1-mediated disease of the central nervous system (CNS) (Pender, 1995) . RR-EAE mimics many of the clinical and pathological features of the human demyelinating disease multiple sclerosis (MS). RR-EAE induced in SJL/J mice using an encephalitogenic peptide of myelin proteolipid protein ) emulsified in complete Freund's adjuvant (CFA) is characterized by an initial acute attack that lasts an average of 7 days which is then followed by an irregular RR phase (McRae et al., 1995; Tsunoda and Fujinami, 1996; Whitham et al., 1991) . While the pathogenesis of MS is unknown, several features, including genetics, age and environmental factors, contribute to the disease. Epidemiologic studies have demonstrated that the prevalence of MS is low around the equatorial belt of the world and as one progresses north and south from this region, the incidence of MS increases (Kurtzke, 1993 , reviewed in Libbey and Fujinami, 2002 , 2003 . Migration studies have shown that individuals moving after the age of 15 from an area of high-risk for MS to an area of low incidence of MS retain their high-risk for MS phenotype. Conversely, individuals migrating before the age of 15 acquire the low-risk phenotype of the area to which they have moved. These data have been interpreted as indicating that infections early in life in high-risk or high endemic MS areas contribute to or imprint the body's immune system to the high-risk MS phenotype. The converse of this is that infections early in life in the low-risk MS regions may actually protect individuals from developing MS (Granieri et al., 2001; Granieri and Casetta, 1997; Kurtzke, 1993) . In addition, there are several reports indicating that exacerbations of MS occur in close association with microbial infections (Álvarez-Lafuente et al., 2006; Andersen et al., 1993; Berti et al., 2002; Buljevac et al., 2002; Christensen, 2007; Correale et al., 2006; De Keyser et al., 1998; Edwards et al., 1998; Gilden, 2002; Granieri et al., 2001; Kriesel et al., 2004; Kriesel and Sibley, 2005; Marrie et al., 2000; Metz et al., 1998; Panitch, 1994; Rapp et al., 1995; Sibley et al., 1985; Sospedra and Martin, 2006; Wandinger et al., 2000) . Therefore from an epidemiologic standpoint, infections, whether viral, bacterial, or parasitic, probably contribute to the pathogenesis of MS.
Molecular mimicry is a sharing of immunologic determinants between a microbe, virus or bacteria, and the host. We have previously demonstrated that recombinant viruses encoding self-proteins could either prime for autoimmune CNS disease or protect from autoimmune CNS disease (Barnett et al., 1993 (Barnett et al., , 1996 Wang et al., 1999; Wang and Fujinami, 1997) . We have also reported that vaccination with naked DNA (Tsunoda et al., 1999) and DNA encoding self-CNS Journal of Neuroimmunology 204 (2008) 92-100 
